Clinical trials: Hepatitis C, Chronic
Hepatitis C
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
A Study to assess the general safety and tolerability of the administration of a 3-dose prime/boost regimen of the MRKAd5 HIV-1 gag vaccine (V520) in subjects with chronic hepatitis C virus infection.
- Trial name
- NCT00857311
- Testing
- MRKAd5 HIV-1 gag vaccine (V520), Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response (RVR) i.e., undetectable hepatitis C virus…
- Trial name
- NCT00704184
- Testing
- Comparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
This is a randomized, multi-site, placebo-controlled trial of a fixed dose combination (FDC) of grazoprevir (MK-5172) 100 mg + elbasvir (MK-8742) 50 mg in participants with chronic Hepatitis C Virus (HCV) genotype (GT) 1, GT4 or…
- Trial name
- NCT02252016
- Testing
- Grazoprevir + Elbasvir
- Volunteers
- 159 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.
- Trial name
- ASTRAL-5 (NCT02480712)
- Testing
- SOF/VEL
- Where
- 15 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic, Hepacivirus
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)
The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness.
- Trial name
- NCT00705263
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 113 people
- Sponsor
- Schering-Plough
Hepatitis C
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
The objective of this trial is to collect evidence for the safety and efficacy of 24 weeks of treatment with BI 201335 240 mg in combination with 24 or 48 weeks of Pegylated Interferon (PegIFN) and ribavirin (RBV) in treatment…
- Trial name
- NCT01330316
- Testing
- BI 201335, PegIFN/RBV
- Where
- 87 sites in United States, Austria and 13 more
- Volunteers
- 119 people
- Sponsor
- Boehringer Ingelheim
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C, Chronic
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to…
- Trial name
- ACTIVATE (NCT01364090)
- Testing
- Pegylated interferon alfa 2b, Ribavirin
- Where
- 17 sites in Australia, Belgium and 5 more
- Volunteers
- 93 people
- Sponsor
- Kirby Institute
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection
The primary objectives of this study are to evaluate the effect of sustained virologic response (SVR) on cerebral metabolism as determined by magnetic resonance spectroscopy (MRS) and on neurocognition as measured by…
- Trial name
- NCT02219685
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
The study evaluates safety and efficacy of vaniprevir (MK7009), when administered with Pegylated-Interferon (peg-IFN) and Ribavirin, in Japanese patients with Hepatitis C infection.
- Trial name
- NCT00880763
- Testing
- Vaniprevir, Pegylated Interferon (peg-IFN), Ribavirin
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered…
- Trial name
- NCT04382404
- Testing
- Sofosbuvir-Velpatasvir Drug Combination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Catherine Anne Chappell
Hepatitis C, Chronic
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the pharmacokinetic interactions between simeprevir and ledipasvir in a treatment regimen consisting of simeprevir (SMV), sofosbuvir (SOF), and ledipasvir (LDV) in treatment-naive…
- Trial name
- NCT02421211
- Testing
- Simeprevir (SMV), Ledipasvir (LDV), Sofosbuvir (SOF)
- Where
- 4 sites in Belgium
- Volunteers
- 41 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis C, Chronic, Hepatitis C
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
The objective of this study is to evaluate patient satisfaction in hepatitis C patients receiving PegIntron pen plus Rebetol. The rationale is that the effectiveness of treatment is correlated with adherence to the prescribed…
- Trial name
- NCT00704717
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031) pen, Rebetol (ribavirin; SCH 18908)
- Volunteers
- 185 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Thrombocytopenia
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
- Trial name
- NCT01355289
- Testing
- Avatrombopag, Pegylated interferon (PEG-IFN), Telaprevir
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Hepatitis C
Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
This study will determine the efficacy of PEG-Intron (SCH 54031) in participants with chronic Hepatitis C virus (HCV) infection who have not been previously treated with interferon.
- Trial name
- NCT03537274
- Testing
- PEG-Intron, Interferon Alfa-2B
- Volunteers
- 1,224 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin, Telaprevir) for the treatment of early chronic Hepatitis C Virus (HCV) infection.
- Trial name
- DARE-C (NCT01743521)
- Testing
- TPV/PEG-IFN/RBV
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Kirby Institute
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.
- Trial name
- CERTAIN-2 (NCT02723084)
- Testing
- ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV)
- Volunteers
- 136 people
- Sponsor
- AbbVie
Hepatitis C
SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
Researchers want to see whether Sho-saiko-to (SST) can help in patients with chronic hepatitis C. Chronic hepatitis C may cause swelling within the liver and this can lead to scar tissue.
- Trial name
- NCT00590564
- Testing
- Sho-saiko-to
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Hepatitis C
Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Background: Chronic hepatitis C is a serious liver disease. Current treatments have side effects. New drugs have been developed, but they work better in some people than others. Researchers want to learn why.
- Trial name
- NCT02468648
- Testing
- Sofosbuvir, GS-5816
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)